To evaluate the safety of sequentially administered recombinant (r) human (h) interleukin-12 (IL-12) and interferon alfa-2b (IFN-α-2b) in patients with advanced cancer and to determine the effects of ...
SAN JOSE, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback